Feasibility, Reliability, and Clinical Validity of Eye Tracking and Pupillometry as an Outcome Measure for Clinical Trials in Fragile X Syndrome (FXS)

被引：0
|
作者：
Scaggs, F.
Farzin, F.
Hervey, C.
Hessl, D.
Berry-Kravis, E.
机构：
来源：
ANNALS OF NEUROLOGY | 2010年 / 68卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [41] Development of a Conceptual Model to Inform a Clinical Outcome Assessment Strategy in Adolescents and Young Adults with Fragile X Syndrome
    Lee, Anna
    Cordeiro, Lisa
    Marshall, Chris
    Wilson, Emma
    Visootsak, Jeannie
    NEUROLOGY, 2019, 92 (15)
  • [42] Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity (vol 12, 10, 2020)
    Abbeduto, Leonard
    Berry-Kravis, Elizabeth
    Sterling, Audra
    Sherman, Stephanie
    Edgin, Jamie O.
    McDuffie, Andrea
    Hoffmann, Anne
    Hamilton, Debra
    Nelson, Michael
    Aschkenasy, Jeannie
    Thurman, Angela John
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2020, 12 (01)
  • [43] A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials
    Raspa, Melissa
    Bann, Carla M.
    Gwaltney, Angela
    Benke, Timothy A.
    Fu, Cary
    Glaze, Daniel G.
    Haas, Richard
    Heydemann, Peter
    Jones, Mary
    Kaufmann, Walter E.
    Lieberman, David
    Marsh, Eric
    Peters, Sarika
    Ryther, Robin
    Standridge, Shannon
    Skinner, Steven A.
    Percy, Alan K.
    Neul, Jeffrey L.
    AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2020, 125 (06): : 493 - 509
  • [44] Constructing and evaluating a validity argument for a performance outcome measure for clinical trials: An example using the Multi-luminance Mobility Test
    Weinfurt, Kevin P.
    CLINICAL TRIALS, 2022, 19 (02) : 184 - 193
  • [45] Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]
    Merikle, Elizabeth
    Patel, Vanessa
    Dobbins, Thomas
    OQuinn, Stephen
    Tich, Nancy
    Palumbo, Joseph
    BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S143 - S143
  • [46] Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: A feasibility study
    Martin F.
    Inoue E.
    Cortese I.C.M.
    de Almeida Kruschewsky R.
    Adonis A.
    Grassi M.F.R.
    Galvão-Castro B.
    Jacobson S.
    Yamano Y.
    Taylor G.P.
    Bland M.
    Pilot and Feasibility Studies, 1 (1)
  • [47] Measuring Health-Related Physical Fitness in Physiotherapy Practice: Reliability Validity, and Feasibility of Clinical Field Tests and a Patient-Reported Measure
    Tveter, Anne Therese
    Dagfinrud, Hanne
    Moseng, Tuva
    Holm, Inger
    JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY, 2014, 44 (03): : 206 - 216
  • [48] The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis - Relative validity of scales in relation to clinical measures of arthritis severity
    Kosinski, M
    Keller, SD
    Ware, JE
    Hatoum, HT
    Kong, SXD
    MEDICAL CARE, 1999, 37 (05) : MS23 - MS39
  • [49] The Urgent Need for Molecular Imaging to Confirm Target Engagement for Clinical Trials of Fragile X Syndrome and Other Subtypes of Autism Spectrum Disorder
    Brasic, James Robert
    Mathur, Anil K.
    Budimirovic, Dejan B.
    ARCHIVES OF NEUROSCIENCE, 2019, 6
  • [50] Prodromal Markers of Upper Limb Deficits in FMR1 Premutation Carriers and Quantitative Outcome Measures for Future Clinical Trials in Fragile X-associated Tremor/Ataxia Syndrome
    O'Keefe, Joan A.
    Bang, Deborah
    Robertson, Erin E.
    Biskis, Alexandras
    Ouyang, Bichun
    Liu, Yuanqing
    Pal, Gian
    Berry-Kravis, Elizabeth
    Hall, Deborah A.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2020, 7 (07): : 810 - 819
12345